HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction.

Overexpression of receptor tyrosine kinases (RTK), including members of the HER family, has prognostic and therapeutic significance in invasive esophagogastric carcinoma. RTK expression in premalignant gastroesophageal lesions has not been extensively explored. Formalin-fixed paraffin-embedded tissu...

Full description

Bibliographic Details
Main Authors: Brett L Ecker, Laura Taylor, Paul J Zhang, Emma E Furth, Gregory G Ginsberg, Matthew T McMillan, Jashodeep Datta, Brian J Czerniecki, Robert E Roses
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4999185?pdf=render
id doaj-39dd41e1575843adacf2439338037112
record_format Article
spelling doaj-39dd41e1575843adacf24393380371122020-11-25T02:10:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01118e016178110.1371/journal.pone.0161781HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction.Brett L EckerLaura TaylorPaul J ZhangEmma E FurthGregory G GinsbergMatthew T McMillanJashodeep DattaBrian J CzernieckiRobert E RosesOverexpression of receptor tyrosine kinases (RTK), including members of the HER family, has prognostic and therapeutic significance in invasive esophagogastric carcinoma. RTK expression in premalignant gastroesophageal lesions has not been extensively explored. Formalin-fixed paraffin-embedded tissue samples of esophageal biopsy specimens from 73 patients with Barrett's esophagus with either low-grade dysplasia (LGD) (n = 32) or high-grade dysplasia (HGD) (n = 59) were analyzed for HER1, HER2, HER3 and CMET expression by immunohistochemistry (IHC). Immunophenotype was correlated with histologic and clinical features. High-grade dysplasia (HGD) was associated with overexpression of HER1 (20.7% vs. 3.1%, p = 0.023), HER2 (5.3% vs. 0.0%, p = 0.187) and HER3 (47.4% vs. 9.4%, p<0.001) compared to low-grade dysplasia (LGD). There was a significant association of HER2 (20.0% vs. 2.1%, p = 0.022) and HER3 (80.0% vs. 40.4%, p = 0.023) overexpression in HGD lesions associated with foci of invasive carcinoma compared to those without invasive foci. Overexpression of CMET was observed in 42.9% of specimens, was increasingly observed with HGD compared to LGD (58.3% vs. 36.7%, p = 0.200), and was most often co-expressed with HER3 (62.5% of HER3-positive specimens vs. 38.2% of HER3-negative specimens, p = 0.212). In summary, HER3 is frequently overexpressed in high-grade dysplastic lesions of the gastroesophageal junction and may be a marker of invasive progression. These data provide rationale for targeting HER2 and HER3 pathways in an early disease setting to prevent disease progression.http://europepmc.org/articles/PMC4999185?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Brett L Ecker
Laura Taylor
Paul J Zhang
Emma E Furth
Gregory G Ginsberg
Matthew T McMillan
Jashodeep Datta
Brian J Czerniecki
Robert E Roses
spellingShingle Brett L Ecker
Laura Taylor
Paul J Zhang
Emma E Furth
Gregory G Ginsberg
Matthew T McMillan
Jashodeep Datta
Brian J Czerniecki
Robert E Roses
HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction.
PLoS ONE
author_facet Brett L Ecker
Laura Taylor
Paul J Zhang
Emma E Furth
Gregory G Ginsberg
Matthew T McMillan
Jashodeep Datta
Brian J Czerniecki
Robert E Roses
author_sort Brett L Ecker
title HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction.
title_short HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction.
title_full HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction.
title_fullStr HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction.
title_full_unstemmed HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction.
title_sort her3 expression is a marker of tumor progression in premalignant lesions of the gastroesophageal junction.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2016-01-01
description Overexpression of receptor tyrosine kinases (RTK), including members of the HER family, has prognostic and therapeutic significance in invasive esophagogastric carcinoma. RTK expression in premalignant gastroesophageal lesions has not been extensively explored. Formalin-fixed paraffin-embedded tissue samples of esophageal biopsy specimens from 73 patients with Barrett's esophagus with either low-grade dysplasia (LGD) (n = 32) or high-grade dysplasia (HGD) (n = 59) were analyzed for HER1, HER2, HER3 and CMET expression by immunohistochemistry (IHC). Immunophenotype was correlated with histologic and clinical features. High-grade dysplasia (HGD) was associated with overexpression of HER1 (20.7% vs. 3.1%, p = 0.023), HER2 (5.3% vs. 0.0%, p = 0.187) and HER3 (47.4% vs. 9.4%, p<0.001) compared to low-grade dysplasia (LGD). There was a significant association of HER2 (20.0% vs. 2.1%, p = 0.022) and HER3 (80.0% vs. 40.4%, p = 0.023) overexpression in HGD lesions associated with foci of invasive carcinoma compared to those without invasive foci. Overexpression of CMET was observed in 42.9% of specimens, was increasingly observed with HGD compared to LGD (58.3% vs. 36.7%, p = 0.200), and was most often co-expressed with HER3 (62.5% of HER3-positive specimens vs. 38.2% of HER3-negative specimens, p = 0.212). In summary, HER3 is frequently overexpressed in high-grade dysplastic lesions of the gastroesophageal junction and may be a marker of invasive progression. These data provide rationale for targeting HER2 and HER3 pathways in an early disease setting to prevent disease progression.
url http://europepmc.org/articles/PMC4999185?pdf=render
work_keys_str_mv AT brettlecker her3expressionisamarkeroftumorprogressioninpremalignantlesionsofthegastroesophagealjunction
AT laurataylor her3expressionisamarkeroftumorprogressioninpremalignantlesionsofthegastroesophagealjunction
AT pauljzhang her3expressionisamarkeroftumorprogressioninpremalignantlesionsofthegastroesophagealjunction
AT emmaefurth her3expressionisamarkeroftumorprogressioninpremalignantlesionsofthegastroesophagealjunction
AT gregorygginsberg her3expressionisamarkeroftumorprogressioninpremalignantlesionsofthegastroesophagealjunction
AT matthewtmcmillan her3expressionisamarkeroftumorprogressioninpremalignantlesionsofthegastroesophagealjunction
AT jashodeepdatta her3expressionisamarkeroftumorprogressioninpremalignantlesionsofthegastroesophagealjunction
AT brianjczerniecki her3expressionisamarkeroftumorprogressioninpremalignantlesionsofthegastroesophagealjunction
AT roberteroses her3expressionisamarkeroftumorprogressioninpremalignantlesionsofthegastroesophagealjunction
_version_ 1724919510215950336